Show simple item record

dc.contributor.authorSiskind, Dan J
dc.contributor.authorLeung, Janni
dc.contributor.authorRussell, Anthony W
dc.contributor.authorWysoczanski, Daniel
dc.contributor.authorKisely, Steve
dc.date.accessioned2018-01-04T01:30:53Z
dc.date.available2018-01-04T01:30:53Z
dc.date.issued2016
dc.identifier.issn1932-6203
dc.identifier.doi10.1371/journal.pone.0156208
dc.identifier.urihttp://hdl.handle.net/10072/100594
dc.description.abstractBackground Although clozapine is the gold-standard for treatment refractory schizophrenia, it has the worst metabolic profile of all antipsychotics. This is partly mediated by clozapine’s impact on glucagon-like peptide (GLP-1). There is an absence of robust evidence for effective treatments for clozapine associated weight gain and metabolic syndrome. Metformin, with its role in increasing GLP-1 may aid weight loss among people on clozapine. Methods We conducted a systematic-review and meta-analysis of metformin versus placebo for change in weight and metabolic syndrome for people on clozapine without diabetes mellitus. We searched the Cochrane Schizophrenia Group’s trial register, Pubmed and Embase, as well as the following Chinese databases: the Chinese Biomedical Literature Service System and China Knowledge Resource Integrated Database. This was supplemented by hand searches of key papers. Results Eight studies, of which three were from Chinese databases, with 478 participants were included. We found that metformin was superior to placebo in terms of weight loss (-3.12kg, 95%CI -4.88kg to -1.37kg) and BMI (-1.18kg/m2, 95%CI -1.76kg/m2 to -0.61kg/m2). Metformin significantly improved three of the five components of metabolic syndrome; waist circumference, fasting glucose and triglycerides. Sensitivity analysis on study quality and duration did not greatly impact results. Conclusions Metformin led to clinically meaningful weight loss among people on clozapine, and may reduce the rates of metabolic syndrome. Inclusion of metformin into the treatment protocols of people on clozapine, as tolerated, should be considered.
dc.description.peerreviewedYes
dc.languageEnglish
dc.language.isoeng
dc.publisherPublic Library of Sciences
dc.relation.ispartofpagefrome0156208-1
dc.relation.ispartofpagetoe0156208-15
dc.relation.ispartofissue6
dc.relation.ispartofjournalPLoS One
dc.relation.ispartofvolume11
dc.subject.fieldofresearchClinical pharmacology and therapeutics
dc.subject.fieldofresearchcode321402
dc.titleMetformin for Clozapine Associated Obesity: A Systematic Review and Meta-Analysis
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttps://creativecommons.org/licenses/by/4.0/
dc.description.versionVersion of Record (VoR)
gro.rights.copyright© 2016 Siskind et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
gro.hasfulltextFull Text
gro.griffith.authorKisely, Steve R.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record